Evaluation of Tazemetostat as a Therapeutically Relevant Substance in Biliary Tract Cancer

Dino Bekric; Daniel Neureiter; Celina Ablinger; Heidemarie Dobias; Marlena Beyreis; Markus Ritter; Martin Jakab; Johannes Bischof; Ulrich Koller; Tobias Kiesslich; Christian Reinhard Mayr

doi:10.3390/cancers15051569

Evaluation of Tazemetostat as a Therapeutically Relevant Substance in Biliary Tract Cancer

Dino Bekric (Erstautor/-in), Daniel Neureiter (Co-Autor/-in), Celina Ablinger, Heidemarie Dobias (Co-Autor/-in), Marlena Beyreis (Co-Autor/-in), Markus Ritter (Co-Autor/-in), Martin Jakab (Co-Autor/-in), Johannes Bischof (Co-Autor/-in), Ulrich Koller (Co-Autor/-in), Tobias Kiesslich (Co-Autor/-in), Christian Reinhard Mayr^* (Letztautor/-in)

^*Korrespondierende/r Autor/-in für diese Arbeit

Publikation: Beitrag in Fachzeitschrift › Originalarbeit › Begutachtung

7 Quellenangaben (Web of Science)

Originalsprache	Englisch
Fachzeitschrift	Cancers
Jahrgang	15
Ausgabenummer	5
DOIs	https://doi.org/10.3390/cancers15051569
Publikationsstatus	Veröffentlicht - 2 März 2023

Zugriff auf Dokument

10.3390/cancers15051569

Dieses zitieren

@article{40291a64297a43df9a18a14b91e4beb8,

title = "Evaluation of Tazemetostat as a Therapeutically Relevant Substance in Biliary Tract Cancer",

keywords = "CARCINOMA-CELL-LINE, SELECTIVE-INHIBITION, EZH2, GALLBLADDER, EXPRESSION, OVEREXPRESSION, PROLIFERATION, ESTABLISHMENT, PROGRESSION, METASTASIS",

author = "Dino Bekric and Daniel Neureiter and Celina Ablinger and Heidemarie Dobias and Marlena Beyreis and Markus Ritter and Martin Jakab and Johannes Bischof and Ulrich Koller and Tobias Kiesslich and Mayr, {Christian Reinhard}",

note = "Bekric, Dobias, Beyreis, Ritter, Jakab, Kiesslich, Mayr: Center of Physiology, Pathophysiology and Biophysics, Institute of Physiology and Pathophysiology, Paracelsus Medical University, 5020 Salzburg, Austria; Daniel Neureiter: Institute of Pathology, Paracelsus Medical University/University Hospital Salzburg (SALK), 5020 Salzburg, Austria; Johannes Bischof, Ulrich Koller: Research Program for Molecular Therapy of Genodermatoses, EB House Austria, Department of Dermatology and Allergology, Paracelsus Medical University/University Hospital Salzburg (SALK), 5020 Salzburg, Austria; Kiesslich, Mayr: Department of Internal Medicine I, Paracelsus Medical University/University Hospital Salzburg (SALK), 5020 Salzburg, Austria; Ritter: Gastein Research Institute, Paracelsus Medical University, 5020 Salzburg, Austria; Ludwig Boltzmann Institute for Arthritis and Rehabilitation, Paracelsus Medical University, 5020 Salzburg, Austria; Ablinger: Institute of Pharmacy, Paracelsus Medical University, 5020 Salzburg, Austria",

year = "2023",

month = mar,

day = "2",

doi = "10.3390/cancers15051569",

language = "English",

volume = "15",

journal = "Cancers",

issn = "2072-6694",

publisher = "MDPI",

number = "5",

}

TY - JOUR

T1 - Evaluation of Tazemetostat as a Therapeutically Relevant Substance in Biliary Tract Cancer

AU - Bekric, Dino

AU - Neureiter, Daniel

AU - Ablinger, Celina

AU - Dobias, Heidemarie

AU - Beyreis, Marlena

AU - Ritter, Markus

AU - Jakab, Martin

AU - Bischof, Johannes

AU - Koller, Ulrich

AU - Kiesslich, Tobias

AU - Mayr, Christian Reinhard

N1 - Bekric, Dobias, Beyreis, Ritter, Jakab, Kiesslich, Mayr: Center of Physiology, Pathophysiology and Biophysics, Institute of Physiology and Pathophysiology, Paracelsus Medical University, 5020 Salzburg, Austria; Daniel Neureiter: Institute of Pathology, Paracelsus Medical University/University Hospital Salzburg (SALK), 5020 Salzburg, Austria; Johannes Bischof, Ulrich Koller: Research Program for Molecular Therapy of Genodermatoses, EB House Austria, Department of Dermatology and Allergology, Paracelsus Medical University/University Hospital Salzburg (SALK), 5020 Salzburg, Austria; Kiesslich, Mayr: Department of Internal Medicine I, Paracelsus Medical University/University Hospital Salzburg (SALK), 5020 Salzburg, Austria; Ritter: Gastein Research Institute, Paracelsus Medical University, 5020 Salzburg, Austria; Ludwig Boltzmann Institute for Arthritis and Rehabilitation, Paracelsus Medical University, 5020 Salzburg, Austria; Ablinger: Institute of Pharmacy, Paracelsus Medical University, 5020 Salzburg, Austria

PY - 2023/3/2

Y1 - 2023/3/2

KW - CARCINOMA-CELL-LINE

KW - SELECTIVE-INHIBITION

KW - EZH2

KW - GALLBLADDER

KW - EXPRESSION

KW - OVEREXPRESSION

KW - PROLIFERATION

KW - ESTABLISHMENT

KW - PROGRESSION

KW - METASTASIS

U2 - 10.3390/cancers15051569

DO - 10.3390/cancers15051569

M3 - Original Article

C2 - 36900361

SN - 2072-6694

VL - 15

JO - Cancers

JF - Cancers

IS - 5

ER -